Sex-Specific Silencing of X-Linked Genes by Xist RNA PNAS PLUS
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Revealing the Mechanism of Xist-Mediated Silencing
Revealing the Mechanism of Xist-mediated Silencing Thesis by Chun-Kan Chen In Partial Fulfillment of the Requirements for the degree of Doctor of Philosophy CALIFORNIA INSTITUTE OF TECHNOLOGY Pasadena, California 2018 Defended November 1, 2017 ii 2017 Chun-Kan Chen ORCID: 0000-0002-1194-9137 iii ACKNOWLEDGEMENTS First of all, I’d like to thank my great mentor, Dr. Mitch Guttman (California Institute of Technology, Pasadena, CA), who led me to become an independent researcher and gave me valuable advice that guided me to accomplish this thesis. He has always been supportive of my future plans and career goals. I really enjoyed every discussion we have had. We often generated some interesting ideas for projects during our discussions. I would also like to send my thanks to my lab mates, Amy Chow, Mario Blanco, and Erik Aznauryan, who helped me with many experiments to move the project forward. I’d like to acknowledge Dr. Kathrin Plath (University of California, Los Angeles, Los Angeles, CA) for the collaboration and his critical comments on this project. Also, I want to thank Jesse Engreitz and Patrick McDonel, who provided helpful comments and suggestions to the project. I want to thank my parents, brother, and parents-in-law who provided both instrumental and emotional support to assist me in completing my Ph.D. degree. I also want to thank my friends, Lily Chen, Pei-Ying Lin, Tzu-Yao Wang, and Wei Li, for giving me valuable social support during my years in graduate school. Last but not least, I would like to send my special thanks to my wife, Christine Juang, who has always been supportive. -
Association of BRCA1 with the Inactive X Chromosome and XIST RNA
FirstCite Published online e-publishing Association of BRCA1 with the inactive X chromosome and XIST RNA Shridar Ganesan1, Daniel P. Silver1, Ronny Drapkin1, Roger Greenberg1, Jean Feunteun2 and David M. Livingston1* 1The Dana-Farber Cancer Institute and Harvard Medical School, 1 Jimmy Fund Way, Boston, MA 02115, USA 2Laboratoire de Genetique et Transfert de Gene, Institut Gustav-Roussy, Villejuif 94805, France Breast cancer, early onset 1 (BRCA1) encodes a nuclear protein that participates in breast and ovarian cancer suppression. The molecular basis for the gender and tissue specificity of the BRCA1 cancer syn- drome is unknown. Recently, we observed that a fraction of BRCA1 in female cells is localized on the inactive X chromosome (Xi). Chromatin immunoprecipitation (ChIP) experiments have demonstrated that BRCA1 physically associates with Xi-specific transcript (XIST) RNA, a non-coding RNA known to coat Xi and to participate in the initiation of its inactivation during early embryogenesis. Cells lacking wild- type BRCA1 show abnormalities in Xi, including lack of proper XIST RNA localization. Reintroduction of wild-type, but not mutant, BRCA1 can correct this defect in XIST localization in these cells. Depletion of BRCA1 in female diploid cells led to a defect in proper XIST localization on Xi and in the development of normal Xi heterchromatic superstructure. Moreover, depletion of BRCA1 led to an increased likelihood of re-expression of a green fluorescent protein (GFP) reporter gene embedded on Xi. Taken together, these findings are consistent with a model in which BRCA1 function contributes to the maintenance of proper Xi heterochromatin superstructure. Although the data imply a novel gender-specific consequence of BRCA1 loss, the relevance of the BRCA1/Xi function to the tumour suppressor activity of BRCA1 remains unclear and needs to be tested. -
Dynamics of Gene Silencing During X Inactivation Using Allele-Specific RNA-Seq Hendrik Marks1*, Hindrik H
Marks et al. Genome Biology (2015) 16:149 DOI 10.1186/s13059-015-0698-x RESEARCH Open Access Dynamics of gene silencing during X inactivation using allele-specific RNA-seq Hendrik Marks1*, Hindrik H. D. Kerstens1, Tahsin Stefan Barakat3, Erik Splinter4, René A. M. Dirks1, Guido van Mierlo1, Onkar Joshi1, Shuang-Yin Wang1, Tomas Babak5, Cornelis A. Albers2, Tüzer Kalkan6, Austin Smith6, Alice Jouneau7, Wouter de Laat4, Joost Gribnau3 and Hendrik G. Stunnenberg1* Abstract Background: During early embryonic development, one of the two X chromosomes in mammalian female cells is inactivated to compensate for a potential imbalance in transcript levels with male cells, which contain a single X chromosome. Here, we use mouse female embryonic stem cells (ESCs) with non-random X chromosome inactivation (XCI) and polymorphic X chromosomes to study the dynamics of gene silencing over the inactive X chromosome by high-resolution allele-specific RNA-seq. Results: Induction of XCI by differentiation of female ESCs shows that genes proximal to the X-inactivation center are silenced earlier than distal genes, while lowly expressed genes show faster XCI dynamics than highly expressed genes. The active X chromosome shows a minor but significant increase in gene activity during differentiation, resulting in complete dosage compensation in differentiated cell types. Genes escaping XCI show little or no silencing during early propagation of XCI. Allele-specific RNA-seq of neural progenitor cells generated from the female ESCs identifies three regions distal to the X-inactivation center that escape XCI. These regions, which stably escape during propagation and maintenance of XCI, coincide with topologically associating domains (TADs) as present in the female ESCs. -
Anti-RBM3 Antibody [HB9] (ARG23691)
Product datasheet [email protected] ARG23691 Package: 50 μg anti-RBM3 antibody [HB9] Store at: -20°C Summary Product Description Mouse Monoclonal antibody [HB9] recognizes RBM3 Tested Reactivity Hu Tested Application ICC/IF Specificity The antibody reacts against the recombinant human RBM3 full length under oxidative conditions without DTT or under reducing conditions with DTT. Cross reactivity of the antibody with the recombinant human Cold inducible Binding protein (CIRBP, full length 20.5 kDa) could not be detected. The apparent MW of hRBM3 in SDS-PAGE is ~17 kDa. Host Mouse Clonality Monoclonal Clone HB9 Isotype IgG1 Target Name RBM3 Antigen Species Human Immunogen Human RNA-binding protein 3. Conjugation Un-conjugated Alternate Names RNPL; IS1-RNPL; RNA-binding motif protein 3; RNA-binding protein 3 Application Instructions Application table Application Dilution ICC/IF 1:50 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 17 kDa Properties Form Liquid Purification Purification with Protein G. The IgG1 fraction was purified by affinity chromatography. Buffer PBS (pH 7.4) and 0.01% Sodium azide. Preservative 0.01% Sodium azide Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C or below. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. www.arigobio.com 1/2 Note For laboratory research only, not for drug, diagnostic or other use. -
Identification of the Rna Binding Protein Rbm3 As a Novel Effector of Β-Catenin Signaling and Colon Cancer Stem Cells
IDENTIFICATION OF THE RNA BINDING PROTEIN RBM3 AS A NOVEL EFFECTOR OF β-CATENIN SIGNALING AND COLON CANCER STEM CELLS By Anand Venugopal Submitted to the graduate degree program in Molecular and Integrative Physiology and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. ________________________________ Chairperson Shrikant Anant, Ph.D. ________________________________ Roy Jensen, M.D. ________________________________ Andrew Godwin, Ph.D. ________________________________ Danny Welch, Ph.D. ________________________________ John Wood, Ph.D. Date Defended: ________________________________March 14, 2014 The Dissertation Committee for Anand Venugopal certifies that this is the approved version of the following dissertation: IDENTIFICATION OF THE RNA BINDING PROTEIN RBM3 AS A NOVEL EFFECTOR OF β-CATENIN SIGNALING AND COLON CANCER STEM CELLS ________________________________ Chairperson Shrikant Anant, Ph.D. Date approved: ________________________________March 14, 2014 ii Abstract The intestinal epithelium is one of the fastest renewing tissues within the adult. This renewal is primarily driven by the intestinal epithelial stem cell compartment and homeostasis of this compartment needs to be strictly maintained. Loss of regulation can lead to hyperplasia and subsequent malignant transformation. Moreover, cancers are also thought to contain a stem cell population which maintains long term tumor viability and recurrence following therapy. Therefore, a thorough understanding of the molecular machinery that governs stem cell homeostasis can further our understanding of colon cancer initiation and progression. The RNA binding protein RBM3 is upregulated in many solid tumors including colon, prostate and breast. It also serves as a proto-oncogene inducing the malignant transformation of normal cells when overexpressed. To further characterize the mechanism, we overexpressed RBM3 in DLD-1 and HCT 116 colon cancer cell lines. -
Lncrna Jpx Induces Xist Expression in Mice Using Both Trans and Cis Mechanisms
RESEARCH ARTICLE LncRNA Jpx induces Xist expression in mice using both trans and cis mechanisms Sarah Carmona, Benjamin Lin, Tristan Chou, Katti Arroyo, Sha Sun* Department of Developmental and Cell Biology, Ayala School of Biological Sciences, University of California, Irvine, Irvine, CA, United States of America * [email protected] a1111111111 a1111111111 Abstract a1111111111 a1111111111 Mammalian X chromosome dosage compensation balances X-linked gene products a1111111111 between sexes and is coordinated by the long noncoding RNA (lncRNA) Xist. Multiple cis and trans-acting factors modulate Xist expression; however, the primary competence factor responsible for activating Xist remains a subject of dispute. The lncRNA Jpx is a proposed competence factor, yet it remains unknown if Jpx is sufficient to activate Xist expression in OPEN ACCESS mice. Here, we utilize a novel transgenic mouse system to demonstrate a dose-dependent relationship between Jpx copy number and ensuing Jpx and Xist expression. By localizing Citation: Carmona S, Lin B, Chou T, Arroyo K, Sun S (2018) LncRNA Jpx induces Xist expression in transcripts of Jpx and Xist using RNA Fluorescence in situ Hybridization (FISH) in mouse mice using both trans and cis mechanisms. PLoS embryonic cells, we provide evidence of Jpx acting in both trans and cis to activate Xist. Our Genet 14(5): e1007378. https://doi.org/10.1371/ data contribute functional and mechanistic insight for lncRNA activity in mice, and argue that journal.pgen.1007378 Jpx is a competence factor for Xist activation in vivo. Editor: Gregory S. Barsh, Stanford University School of Medicine, UNITED STATES Received: November 20, 2017 Accepted: April 24, 2018 Author summary Published: May 7, 2018 Long noncoding RNA (lncRNA) have been identified in all eukaryotes but mechanisms Copyright: © 2018 Carmona et al. -
Long Non‑Coding Rnas XIST and MALAT1 Hijack the PD‑L1 Regulatory Signaling Pathway in Breast Cancer Subtypes
ONCOLOGY LETTERS 22: 593, 2021 Long non‑coding RNAs XIST and MALAT1 hijack the PD‑L1 regulatory signaling pathway in breast cancer subtypes AMANY SAMIR1, REDA ABDEL TAWAB2 and HEND M. EL TAYEBI1 1Molecular Pharmacology Research Group, Department of Pharmacology and Toxicology, German University in Cairo, Cairo 11835; 2Department of General Surgery, Ain Shams University, Cairo 11772, Egypt Received July 18, 2020; Accepted January 14, 2021 DOI: 10.3892/ol.2021.12854 Abstract. Long non‑coding RNAs (lncRNAs) have attracted presence of lncRNAs. Therefore, the results of the present widespread attention as potential biological and patho‑ study indicated that although miR‑182‑5p exhibited an onco‑ logical regulators. lncRNAs are involved in several biological genic effect, XIST exerted a dominant effect on the regulation processes in cancer. Triple negative breast cancer (TNBC) is of the PD‑L1 signaling pathway via the inhibition of the onco‑ characterized by strong heterogeneity and aggressiveness. At genic function of MALAT1. present, the implication of microRNAs (miRs) and lncRNAs in immunotherapy has been poorly studied. Nevertheless, Introduction the blockade of immune checkpoints, particularly that of the programmed cell‑death protein‑1/programmed cell‑death In the context of tumor biology, the six hallmarks of cancer ligand‑1 (PD‑L1) axis, is considered as a principle approach in have been proposed to be associated with progressively breast cancer (BC) therapy. The present study aimed to inves‑ growing tumors and to be responsible for the complexity of tigate the interaction between immune‑modulatory upstream neoplastic diseases, and these are limitless replicative poten‑ signaling pathways of the PD‑L1 transcript that could enhance tial, evading apoptosis, self‑sufficiency in growth signals, personalized targeted therapy. -
Human RBM3 ELISA Kit (ARG81349)
Product datasheet [email protected] ARG81349 Package: 96 wells Human RBM3 ELISA Kit Store at: 4°C Summary Product Description ARG81349 Human RBM3 ELISA Kit is an Enzyme Immunoassay kit for the quantification of Human RBM3 in serum and plasma. Tested Reactivity Hu Tested Application ELISA Specificity No significant cross reactivity to Cold inducible Binding protein (CIRBP), human. Target Name RBM3 Conjugation HRP Conjugation Note Substrate: TMB and read at 450 nm. Sensitivity 10 pg/ml Sample Type Serum and plasma. Standard Range 31.25 - 2000 pg/ml Sample Volume 50 µl Alternate Names RNPL; IS1-RNPL; RNA-binding motif protein 3; RNA-binding protein 3 Application Instructions Assay Time ~ 2.5 hours Properties Form 96 well Storage instruction Store the kit at 2-8°C. Keep microplate wells sealed in a dry bag with desiccants. Do not expose test reagents to heat, sun or strong light during storage and usage. Please refer to the product user manual for detail temperatures of the components. Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol RBM3 Gene Full Name RNA binding motif (RNP1, RRM) protein 3 Background This gene is a member of the glycine-rich RNA-binding protein family and encodes a protein with one RNA recognition motif (RRM) domain. Expression of this gene is induced by cold shock and low oxygen tension. A pseudogene exists on chromosome 1. Multiple alternatively spliced transcript variants that are predicted to encode different isoforms have been characterized although some of these variants fit nonsense-mediated decay (NMD) criteria. -
Repetitive Elements in Humans
International Journal of Molecular Sciences Review Repetitive Elements in Humans Thomas Liehr Institute of Human Genetics, Jena University Hospital, Friedrich Schiller University, Am Klinikum 1, D-07747 Jena, Germany; [email protected] Abstract: Repetitive DNA in humans is still widely considered to be meaningless, and variations within this part of the genome are generally considered to be harmless to the carrier. In contrast, for euchromatic variation, one becomes more careful in classifying inter-individual differences as meaningless and rather tends to see them as possible influencers of the so-called ‘genetic background’, being able to at least potentially influence disease susceptibilities. Here, the known ‘bad boys’ among repetitive DNAs are reviewed. Variable numbers of tandem repeats (VNTRs = micro- and minisatellites), small-scale repetitive elements (SSREs) and even chromosomal heteromorphisms (CHs) may therefore have direct or indirect influences on human diseases and susceptibilities. Summarizing this specific aspect here for the first time should contribute to stimulating more research on human repetitive DNA. It should also become clear that these kinds of studies must be done at all available levels of resolution, i.e., from the base pair to chromosomal level and, importantly, the epigenetic level, as well. Keywords: variable numbers of tandem repeats (VNTRs); microsatellites; minisatellites; small-scale repetitive elements (SSREs); chromosomal heteromorphisms (CHs); higher-order repeat (HOR); retroviral DNA 1. Introduction Citation: Liehr, T. Repetitive In humans, like in other higher species, the genome of one individual never looks 100% Elements in Humans. Int. J. Mol. Sci. alike to another one [1], even among those of the same gender or between monozygotic 2021, 22, 2072. -
Non-Coding RNA: X-Chromosome Inactivation Unravelled
RESEARCH HIGHLIGHTS Nature Reviews Molecular Cell Biology | AOP, published online 8 May 2015; doi:10.1038/nrm3998 NON-CODING RNA X-chromosome inactivation unravelled The long non-coding RNA (lncRNA) specific and reproducible set of ten suggesting that SAFA acts to localize Xist (X inactive-specific transcript) is proteins that directly interact with Xist to genomic DNA. Depleting required for the transcriptional silenc- Xist. Of these proteins, knocking Xist binds to SHARP led to the retention of Pol II ing of one X chromosome in each cell, down the genes encoding scaffold SHARP to at Xist-coated X chromosomes, in a process known as X-chromosome attachment factor A (SAFA; also recruit SMRT indicating that SHARP might be inactivation (XCI) that occurs during known as HNRNPU), SMRT- and required for initiating transcriptional mammalian female development. HDAC1-associated repressor protein and activate silencing following Xist localization, Owing to technical limitations, little (SHARP; also known as SPEN or HDAC3 … possibly by recruiting the transcrip- is known about the mechanism of MSX2-interacting protein) and resulting in tional co-repressors SMRT and transcriptional silencing during XCI. lamin-B receptor (LBR) largely abol- HDAC3. Indeed, depleting SMRT McHugh et al. now describe using ished the silencing of XCI‑affected gene silencing or HDAC3 (but not other HDACs) RNA antisense purification followed genes in the male ES cells as well as in abrogated Xist-dependent gene by quantitative mass spectrometry differentiating female ES cells. These silencing. Another feature of XCI (RAP–MS) — a novel approach for three proteins are therefore required is the recruitment of the Polycomb identifying proteins that directly for Xist-mediated gene silencing. -
Agonists Regulate the Expression of Stemness and Differentiation Genes in Brain Tumour Stem Cells
British Journal of Cancer (2012) 106, 1702–1712 & 2012 Cancer Research UK All rights reserved 0007 – 0920/12 www.bjcancer.com PPARg agonists regulate the expression of stemness and differentiation genes in brain tumour stem cells E Pestereva1, S Kanakasabai1 and JJ Bright*,1,2 1 Neuroscience Research Laboratory, Methodist Research Institute, Indiana University Health, 1800 North Capitol Avenue, Noyes Building E504C, 2 Indianapolis, IN 46202, USA; Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA BACKGROUND: Brain tumour stem cells (BTSCs) are a small population of cancer cells that exhibit self-renewal, multi-drug resistance, and recurrence properties. We have shown earlier that peroxisome proliferator-activated receptor gamma (PPARg) agonists inhibit the expansion of BTSCs in T98G and U87MG glioma. In this study, we analysed the influence of PPARg agonists on the expression of stemness and differentiation genes in BTSCs. METHODS: The BTSCs were isolated from T98G and DB29 glioma cells, and cultured in neurobasal medium with epidermal growth factor þ basic fibroblast growth factor. Proliferation was measured by WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2 H-5- tetrazolio]-1,3-benzene disulphonate) and 3H thymidine uptake assays, and gene expression was analysed by quantitative reverse– transcription PCR and Taqman array. The expression of CD133, SRY box 2, and nanog homeobox (Nanog) was also evaluated by western blotting, immunostaining, and flow cytometry. 12,14 RESULTS: We found that PPARg agonists, ciglitazone and 15-deoxy-D -ProstaglandinJ2, inhibited cell viability and proliferation of þ T98G- and DB29-BTSCs. The PPARg agonists reduced the expansion of CD133 BTSCs and altered the expression of stemness and differentiation genes. -
Human RBM3 ELISA Assay Kit
Human RBM3 ELISA Assay Kit BTRBM-001 For quantitative determination of human RNA-binding protein 3 96 Determinations 2°C – 8 °C For research use only Not for diagnostic use RBM3 ELISA Assay Kit 1 of 14 Catalog Number: BTRBM001 www.EagleBio.com Contents Short Review 3 Intended Use 4 Test principle 5 Safety warning and precautions 5 Storage 6 Components of the assay system 6 Sample preparation and storage 7 Critical parameters 7 Preparation of reagents 8 Assay protocol 8 Protocol summary 9 Scheme of the plate 10 Data processing 10 Additional information 11 Specificity 11 Sensitivity 11 Linearity 11 Recovery 11 Reproducibility 12 Troubleshooting 13 Related Products 14 BioTeZ Berlin-Buch GmbH Robert-Rössle-Str. 10, Haus 72 13125 Berlin Tel.: ++49 (0)30-9489 3322 Fax: ++49 (0)30-949 2008 e-mail: [email protected] http://www.biotez.de This manual is valid from May, 2016 RBM3 ELISA Assay Kit 2 of 14 Catalog Number: BTRBM001 www.EagleBio.com Short Review The RNA-binding protein 3 (RBM3) is a member of the glycine-rich RNA-binding protein family. The exact role of the cold shock protein RBM3 is not yet clear [2, 6]. The role of mRNA-binding proteins can be attributed to a regulation of mRNA splicing, stability, transport and ultimately the translation of mRNA into proteins. RBM3 consists of 157 amino acids with a predicted mass of 17 kD (1, 2) and is one of the few proteins that are upregulated at low temperature [3-5]. It is known that RBM3 acts especially in cellular stress (eg.